Thyroid function suppression after initiation of teprotumumab treatment
Sign Up to like & getrecommendations! Published in 2021 at "Endocrine"
DOI: 10.1007/s12020-021-02676-3
Abstract: Teprotumumab, a monoclonal antibody that inhibits the insulin-like growth factor I receptor (IGF-IR), is newly approved for thyroid eye disease [1]. As IGF-IR forms a complex with the thyrotropin receptor (TSHR), mediating the actions of… read more here.
Keywords: thyroid function; initiation teprotumumab; teprotumumab treatment;